Objectives Although recombinant tissue plasminogen activator (r‐tPA) is currently the most
effective treatment for brain ischemic stroke, the 3‐h narrow therapeutic windows severely …

Objectives Recombinant tissue plasminogen activator (rt-PA) is a safe and effective
treatment for acute brain ischemia stroke, albeit with a narrow therapeutic window. We …

Tissue plasminogen activator (tPA) is the only therapeutic agent approved to treat patients
with acute ischemic stroke. The clinical benefits of tPA manifest when the agent is …

To date, reperfusion with tissue plasminogen activator (tPA) remains the gold standard
treatment for ischemic stroke. However, when tPA is given beyond 4.5 hours of stroke onset …

Background The aim of the present study was to evaluate whether early neurologic
improvement (within 30 minutes), as measured using the National Institutes of Health Stroke …

Based on preclinical studies suggesting that recombinant tissue plasminogen activator (rt-
PA) may promote ischemic brain injuries, we investigated in patients the possible risk of …

Tissue plasminogen activator (tPA) thrombolysis continues to be the gold standard therapy
for ischemic stroke. Due to the time-limited treatment window, within 4.5 h of stroke onset …

Background Ischemic stroke is the leading cause of death and disability worldwide. To date,
recombinant tissue plasminogen activator (rt-PA) remains the only safe and effective …

Background and Purpose Recombinant tissue plasminogen activator (rtPA) is the only
effective drug approved by US FDA to treat ischemic stroke, and it contains pleiotropic …

Background and Purpose—Frequencies of treatment with r-tPA (recombinant tissue-type
plasminogen activator) are increasing over the past 15 years. However, published data on …